Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for the menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code
-
Clinical Benefit
Substantial
The actual benefit of the proprietary medicinal products SURGESTONE 0.125 mg, 0.250 mg and 0.500 mg remains substantial in the indication “Menopause (in addition to oestrogen treatment)” in non-hysterectomised postmenopausal women and within the limits defined for the use of the oestrogen treatment with which they are combined when the proprietary medicinal products are used in accordance with the recommendations of the Committee.
Listen
